Roth/MKM analyst Boobalan Pachiyappan downgraded Verona Pharma (NASDAQ: VRNA) from Buy to Neutral with a price target of $107.00.The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE